PFIZER INC Noncash or Part Noncash Acquisition, Debt Assumed
PFIZER INC (PFE) reported Noncash or Part Noncash Acquisition, Debt Assumed of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 · last filed 2018-02-22
- PFIZER INC noncash or part noncash acquisition, debt assumed for fiscal 2017 was $0.00.
- PFIZER INC noncash or part noncash acquisition, debt assumed for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- PFIZER INC noncash or part noncash acquisition, debt assumed for fiscal 2015 was $1.67B.
- PFIZER INC noncash or part noncash acquisition, debt assumed for fiscal 2014 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Debt Assumed 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-22 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-22 |
| 2015-12-31 | $1.67B 10-K · filed 2018-02-22 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-23 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |